Jim Cramer's Lightning Round: Stock Picks on GoodRx, Snowflake, Dover, and Fluor

Stock Analysis: GoodRx and Arrowhead Pharmaceuticals

• 💡 Jim Cramer has not commented on GoodRx recently, implying a neutral or cautious stance.
• ⚠️ Arrowhead Pharmaceuticals is noted for not making money, and Cramer is uncertain if it has the potential for a breakout.

Investment Club Picks: Snowflake

• 💬 Cramer acknowledges Snowflake's volatility, comparing its performance to a political figure's momentum.
• 📈 The stock's movement is attributed to its "cerebral" nature and strong "closing sense."

Cramer's Strong Buy: Dover

• 🚀 Cramer strongly recommends buying Dover "right now tomorrow morning."
• 🎯 He believes the stock was unfairly punished, especially when it dropped despite steel tariffs.
• 💰 The CEO, Tobin, is considered very smart, and Cramer feels the stock should not have traded at 19 times earnings.

Analysis of Fluor

• 📊 Fluor is highlighted for its significant revenue ($16 billion) despite a $4 billion market cap.
• ⚠️ Cramer advises selling Fluor, referencing a past study from 1982 where he recommended selling the stock.
• 🇺🇸 The company operates at the intersection of honoring and remanufacturing, tied to the re-industrialization in the United States.